Tag: KDC-MN-025

  • Piracetam

    2-Oxopyrrolidine acetamide nootropic and positive allosteric modulator of AMPA-type glutamate receptors

    A cyclic GABA derivative synthesized at UCB Pharma as the prototype nootropic agent, distinguished by positive allosteric modulation of AMPA receptors, restoration of membrane fluidity under hypoxic and aging conditions, inhibition of platelet aggregation, and a six-decade clinical record spanning cortical myoclonus, age-related cognitive decline, and acute ischemic stroke.

    Abstract

    Piracetam (2-oxo-1-pyrrolidineacetamide), the founding member of the racetam class and the first compound for which the term “nootropic” was coined, is a cyclic derivative of gamma-aminobutyric acid (GABA) that lacks direct GABAergic receptor activity and instead exerts its principal pharmacological effects through positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptors, restoration of neuronal membrane fluidity, inhibition of voltage-gated N-type calcium channels, and rheological modification of erythrocyte and platelet function. Giurgea formalized this novel pharmacological category in 1972 by coining the term “nootropic” from the Greek nous (mind) and trepein (to bend), establishing criteria that included enhancement of learning and memory, protection of the brain against physical or chemical injury, enhancement of cortical and subcortical control mechanisms, and absence of the pharmacological profile of typical psychotropic drugs. The molecular pharmacology of piracetam centers on a weak but functionally relevant positive allosteric modulation of AMPA receptors, characterized crystallographically by Ahmed and Oswald (2010) as binding at a novel site along the AMPA receptor dimer interface distinct from the aniracetam and cyclothiazide binding sites [1]. A second major mechanism is the restoration of membrane fluidity in aged, hypoxic, or otherwise compromised neuronal membranes through direct interaction with the phospholipid bilayer headgroup region, improving the mobility and function of membrane-embedded receptors and ion channels [2]. A third mechanism, inhibition of voltage-gated N-type calcium channels at low micromolar concentrations (IC50 approximately 3 micromolar in rat cortical neurons), contributes to neuroprotective activity under ischemic conditions [3]. Pharmacokinetics are characterized by near-complete oral absorption (bioavailability approaching 100 percent), absence of hepatic metabolism (no metabolites have been identified in any species), renal excretion of the unchanged compound accounting for greater than 98 percent of the administered dose, and a plasma elimination half-life of approximately 5 hours in adults with normal renal function [4, 5]. The cerebrospinal fluid half-life is approximately 8 hours, consistent with the sustained central nervous system activity observed clinically. The pharmacokinetic profile is uncomplicated by cytochrome P450 interactions, protein binding effects, or hepatic disease sensitivity; the sole clinically relevant pharmacokinetic modifier is renal function, with dose adjustment required in renal impairment and the half-life extending to approximately 59 hours in anuric end-stage renal disease. The clinical evidence base spans six decades and multiple indications. A second major clinical application is age-related cognitive decline and dementia, where a 2002 meta-analysis of 19 double-blind placebo-controlled trials by Waegemans et al. reported a global effect favoring piracetam across a heterogeneous population of older patients with cognitive impairment [8], while a 2012 Cochrane systematic review by Flicker and Grimley Evans concluded that the evidence was suggestive but insufficient to support routine clinical use in dementia [9]. A more recent 2024 systematic review and meta-analysis by Fang et al. of 18 studies and 886 patients reported mixed findings, with some measures of cognitive function showing benefit but overall memory outcomes failing to reach clinical significance [10]. The compound is well tolerated. The principal safety considerations are dose-dependent inhibition of platelet aggregation with prolongation of bleeding time at high doses (a class effect that warrants caution in patients with hemorrhagic risk factors, concurrent anticoagulant therapy, or pre-surgical status), and the requirement for gradual dose tapering in myoclonus patients to avoid withdrawal-related seizure exacerbation [13]. Common adverse events are mild and include nervousness, hyperkinesia, somnolence, and weight gain, with no organ toxicity identified in chronic dosing studies extending to years of treatment. The compound is not approved by the United States Food and Drug Administration and is classified as a dietary supplement ingredient or research compound in the United States; it is a registered prescription medicine in over 60 jurisdictions worldwide. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.